BluMaiden Biosciences
BluMaiden Biosciences discovers human-derived small molecule therapeutics and provides microbiome clinical-trial analytics to help drug developers identify safer, biologically aligned medicines. It uses AI, machine learning, computational biology and computational chemistry — via proprietary platforms such as QuantumBridgeAI and MAIDEN — to translate genomic and microbiome data into candidate small molecules and validate targets. The company offers a mix of cloud-based SaaS and pharma services, integrating with clinical evidence workflows and regulatory-compliant analytics for microbiome trials. BluMaiden targets pharmaceutical and biotech customers, supporting discovery and clinical development of novel human-derived therapeutic leads.
BluMaiden Biosciences
BluMaiden Biosciences discovers human-derived small molecule therapeutics and provides microbiome clinical-trial analytics to help drug developers identify safer, biologically aligned medicines. It uses AI, machine learning, computational biology and computational chemistry — via proprietary platforms such as QuantumBridgeAI and MAIDEN — to translate genomic and microbiome data into candidate small molecules and validate targets. The company offers a mix of cloud-based SaaS and pharma services, integrating with clinical evidence workflows and regulatory-compliant analytics for microbiome trials. BluMaiden targets pharmaceutical and biotech customers, supporting discovery and clinical development of novel human-derived therapeutic leads.